Compare TIPT & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIPT | AURA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.9M | 797.5M |
| IPO Year | 2017 | 2021 |
| Metric | TIPT | AURA |
|---|---|---|
| Price | $18.56 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 192.3K | ★ 770.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $488,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.49 | $4.73 |
| 52 Week High | $27.38 | $9.54 |
| Indicator | TIPT | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 50.21 |
| Support Level | $17.34 | $7.27 |
| Resistance Level | $18.72 | $7.83 |
| Average True Range (ATR) | 0.35 | 0.45 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 64.79 | 38.58 |
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.